Clinical Trials in New York

Showing 6241-6260 of 17,259 trials

Financial Incentives for Smoking Treatment II

NCT03979885

Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.

Smoking CessationTobacco Use Cessation

University of California, Los Angeles1,058 participantsStarted Jan 2020

Los Angeles, California, United States • New York, New York, United States

COMPLETEDPhase 2< 1 mile

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

NCT04676724

This study is intended to evaluate if 12 or 24 weeks of treatment with GSK3228836 followed by up to 24 weeks of pegylated interferon (PegIFN) can increase the rate of hepatitis B virus surface antigen (HBsAg) loss in participants on stable nucleos(t)ide analogue (NA) therapy, and whether virologic response can be sustained once PegIFN treatment is discontinued. Participants will be randomized to receive GSK3228836 for 12 or 24 weeks followed by up to 24 weeks of PegIFN.

Hepatitis B

GlaxoSmithKline108 participantsStarted Jan 2021

Sacramento, California, United States • Iowa City, Iowa, United States • Detroit, Michigan, United States +46 more locations

Financial Incentives for Smoking Treatment II

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

Find Trials by Condition in New York

Brachial Right Ventricle - Endomyocardial Biopsy

Comparision of Air Versus CO2 for Distention During Sigmoidoscopy

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

HCV Seek, Test and Rapid Treatment for Young PWID

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

Lithium for Suicidal Behavior in Mood Disorders

Music During Pulmonary Rehabilitation for Patients With COPD

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

A Study Of PF-04449913 In Select Hematologic Malignancies